or Try an Advanced Search...

    Clinical Development Stocks List

    Symbol Grade Name % Change
    THMO F ThermoGenesis Holdings, Inc. 0.00
    LXRX F Lexicon Pharmaceuticals, Inc. -2.94
    AMPE F Ampio Pharmaceuticals, Inc. 0.00
    VTGN F VistaGen Therapeutics, Inc. -2.68
    CPIX F Cumberland Pharmaceuticals Inc. 0.00
    TCON F TRACON Pharmaceuticals, Inc. -31.40
    REGN F Regeneron Pharmaceuticals, Inc. 0.53
    ONCT F Oncternal Therapeutics, Inc. 5.26
    SAGE F Sage Therapeutics, Inc. 2.14
    SLRX F Salarius Pharmaceuticals, Inc. 5.71
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Information Technology Services Medical Devices
    Related Stock Lists: Biopharmaceutical Cancer Medicine Clinical Trial Drugs Life Sciences Sarcoma Antidepressants Bone Breast Cancer Cartilage Colorectal Cancer Diabetes Disorders Drug Discovery Inflammation Macular Degeneration Macular Edema Monoclonal Antibodies Pain

    Related ETFs - A few ETFs which own one or more of the above listed Clinical Development stocks.

    Symbol Grade Name Weight
    BBP C BioShares Biotechnology Products Fund 9.93
    PBE D PowerShares Dynamic Biotech & Genome 7.96
    MNTL D Tema Neuroscience and Mental Health ETF 6.1
    EKG B First Trust Nasdaq Lux Digital Health Solutions ETF 6.03
    HELX D Franklin Genomic Advancements ETF 5.64
    View all Clinical Development ETFs...
    Compare ETFs
    Compare BBP to HELX Compare EKG to HELX Compare MNTL to HELX

        Clinical Development Stocks Recent News

        Date Stock Title
        Nov 21 SAGE Sage ends dalzanemdor development following Phase II trial failure
        Nov 21 SAGE SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
        Nov 21 SAGE Sage raised to sector perform by RBC in wake of drug failure
        Nov 20 LXRX Lexicon Appoints Ivan H. Cheung to Board of Directors
        Nov 20 SAGE After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
        Nov 20 SAGE Sage slips as Huntington’s Disease therapy fails in mid-stage trial
        Nov 20 SAGE Sage’s string of research failures continues
        Nov 20 SAGE Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
        Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
        Nov 19 REGN Regeneron: The Biotech Stock To Buy Now
        Nov 19 REGN Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
        Nov 19 SAGE CNS Drug Development: Same As It Ever Was
        Nov 18 REGN FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
        Nov 18 LXRX Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week
        Nov 15 REGN FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
        Nov 15 REGN Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
        Nov 15 REGN Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
        Nov 15 SLRX Salarius: Q3 Earnings Snapshot
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Information Technology Services Medical Devices
        Related Stock Lists: Medicine Biopharmaceutical Pain Organ Systems Autoimmune Disease Cancer Central Nervous System Disorders Insomnia Monoclonal Antibodies Monoclonal Antibody Nervous System Disorders Pulmonology Rare Diseases Alcohol Alzheimer's Disease Antibodies Antibody Drug Conjugate Antidepressants Asthma Back Pain
        Clinical Development

        Clinical development is the process of developing a new drug, medical device, or diagnostic test from the initial concept to the point of regulatory approval. It involves a series of steps, including preclinical research, clinical trials, regulatory review, and post-marketing surveillance. The goal of clinical development is to demonstrate the safety and efficacy of a product in order to obtain regulatory approval for marketing.

        Browse All Tags